

## Disclosure of Relevant Financial Relationships with Commercial Companies

The Hope Foundation endorses the Standards of the Accreditation Council for Continuing Medical Education and the Guidelines of the American Medical Association. The Hope Foundation requires that all presentations at CME activities be fair, balanced, free of commercial bias, and fully supported by scientific evidence.

Everyone who is in a position to control the content of a continuing medical education activity is required to disclose relevant relationships with commercial companies whose products or services are discussed in educational presentations. The ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Disclosure of a relationship is not intended to suggest bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

All potential conflicts of interest have been resolved prior to this program.

### A. Financial Disclosures Related to CME Activities and Requirements:

<u>Planner/Faculty Member</u>	<u>Nature of Relationship</u>	<u>Company</u>
<b>Mazin Al-Kasspooles</b>	No Disclosures	
<b>Manmeet Ahluwalia</b>	Consultant	Monteris Medical, AstraZeneca, BMS, Abbvie, Kadmon Pharmaceuticals
	Research Grant	AstraZeneca, BMS, Abbvie
<b>Banu Arun</b>	No Disclosures	
<b>Debra Barton</b>	No Disclosures	
<b>Julie Behm</b>	No Disclosures	
<b>Trever Bivona</b>	No Disclosures	
<b>Charles Blanke</b>	No Disclosures	
<b>Deborah Bruner</b>	Research Grant	PI NrG Oncology NCORP
<b>Young Kwang Chae</b>	No Disclosures	
<b>Helen Chen</b>	No Disclosures	
<b>Jeffrey Chuang</b>	No Disclosures	
<b>Stacey Cohen</b>	No Disclosures	
<b>Claudius Conrad</b>	No Disclosures	
<b>Morgan Cox</b>	No Disclosures	
<b>Jig Deneve</b>	No Disclosures	
<b>Hesham Elhalawani</b>	No Disclosures	
<b>Lee Ellis</b>	Consultant	Roche
	Data Safety Monitoring Committee Member	Roche
<b>Harry Erba</b>	Consultant	Incyte, Jazz, Novartis, Celgene and Agios
	Speaker's Bureau	Incyte, Jazz, Novartis, Celgene and Agios
	Advisory Board	MacroGenics, Seattle Genetics and ImmunoGen
	Chair, DSMB	Glycomimetics
<b>Michael Fisch</b>	Salary	AIM Specialty Health
	Stock/Shareholder	Anthem, Inc.

<b>Jonathan Friedberg</b>	Data Safety Monitoring Cmte	Bayer
<b>Clifton David Fuller</b>	Research Grant	Elekta AB
<b>David Gandara</b>	Consultant	AstraZeneca, Celgene and Merck
<b>Daniel Hayes</b>	Consultant Research Grant Stock/Shareholder Patent	Cepheid (no compensation) Merrimack, Eli Lilly, Menarini/Silicon BioSystems, Veridex, Puma Biotechnology, Pfizer and AstraZeneca Oncimmune LLC and Inbiomotion Royalties from Menarini (patent held by UM)
<b>Norah Lynn Henry</b>	Research Grant	Pfizer, AbbVie, Innocrin, Medivation and Celldex
<b>Dawn Hershman</b>	No Disclosures	
<b>Deirdre Ann Hill</b>	No Disclosures	
<b>Howard Hochster</b>	Consultant	Bayer, Genentech, Merck and Taiho
<b>Johanna Horn</b>	No Disclosures	
<b>Siwen Hu-Lieskovan</b>	Consultant Research Grant	Merck, Amgen and Genmab Pfizer, Neon Therapeutics, Nektar and Genentech
<b>Melinda Irwin</b>	No Disclosures	
<b>Karen Kelly</b>	Data Safety Monitoring Cmte Advisory Board Honorarium Author Royalties Research Grant	AstraZeneca AstraZeneca, Merck, Regeneron, Lilly and AbbVie Merck UpToDate Novartis, EMD Serono, Lilly, Genetech, AbbVie, Celgene, Five Prime, Gilead, Millennium, Synta
<b>Scott Kopetz</b>	Consultant	Genentech and Novartis
<b>Razelle Kurzrock</b>	Research Grant Ownership Interest	Incyte, Genentech, Merck Serono, Pfizer, Sequenom and Foundation Medicine CureMatch, Inc.
<b>Dina Lansey</b>	No Disclosures	
<b>Andrew Lowy</b>	Advisory Board Research Grant	Celgene Syros Pharmaceuticals and Celgene
<b>Anant Madabhushi</b>	Consultant Research Grant Stock/Shareholder	Inspirata, Inc. NIH (Inspirate, PathCore, Inc.) Elucid Bioimaging and Inspirata, Inc.
<b>Joshua Mammen</b>	Research Grant	Menorah Legacy Foundation
<b>Monica Mita</b>	Speaker's Bureau	Genentech (spouse)
<b>Halle Moore</b>	Research Grant	PUMA and AbbVie
<b>Marian Neuhausser</b>	No Disclosures	

<b>Bruno Odisio</b>	No Disclosures	
<b>Paul Okunieff</b>	Consultant Research Grant Stock/Shareholder	GainPep, Inc, DiaCarta, Inc, Entrinsic Health DiaCarta, Inc, Entrinsic Health Enterade, Inc, GainPep, Inc, DiaCarta, Inc
<b>Robert Orlowski</b>	No Disclosures	
<b>C. Kent Osborne</b>	Consultant	AstraZeneca, Novartis and Tolmar
<b>Sandip Pravin Patel</b>	Consultant	BMS, Novartis and AstraZeneca
<b>Lajos Pusztai</b>	Honorarium Research Grant	Merck, AstraZeneca, Almac Diagnostics, Novartis Merck, AstraZeneca, Roche/Genentech and Seattle Genetics
<b>Scott Ramsey</b>	Advisory Board Research	Bayer Kite Pharmaceuticals, Genentech, BMS and Seattle Genetics
<b>Antoni Ribas</b>	Advisory Board Stock/Shareholder	Amgen, Novartis, Merck, Roche/Genentech Cytomx, Five Prime, Arcus Biotherapeutics, PACT Pharma and Tango Therapeutics
<b>Veena Shankaran</b>	No Disclosures	
<b>Irene Tami-Maury</b>	No Disclosures	
<b>Ian Thompson</b>	Honorarium Consultant Speaker's Bureau	Univ. Miami Cancer Center, Univ Oklahoma, Univ Missouri, Fred Hutchinson Cancer Center, Louisiana Cancer Research Center, American Urology Association, New England Medical Johns Hopkins Univ, Partners Healthcare, BioMedical Insights, Magforce, Profound Medical Univ Michigan
<b>David Tuveson</b>	No Disclosures	
<b>Bryan Weiner</b>	No Disclosures	
<b>Courtney Wille</b>	No Disclosures	
<b>Scooter Willis</b>	No Disclosures	
<b>Chadwick Wright</b>	No Disclosures	
<b>George Yoo</b>	No Disclosures	
<b>Jason Zell</b>	No Disclosures	

## B. Financial Disclosures Related to Scientific Activities of SWOG

The relevant policy and process for disclosure of financial conflict of interest within SWOG are governed by Group Policy #35, "Financial Conflict of Interest Policy" (<http://swog.org/Visitors/Download/Policies/Policy35.pdf>) which was established in accordance with (and is consistent with) the Public Health Service regulation entitled "Responsibility of Applicants for promoting Objectivity in Research for which PHS Funding is Sought and Responsible Prospective Contractors" (42 CFR Part 50, 45 CFR 94, final rule published 8/25/2011). Policy #35 is made available to the public via the publicly accessible portion of SWOG's website. Federal regulations require that SWOG management plans be made available within 5 business days upon written request.